Designation was based on early efficacy data demonstrating an 83.3% (10/12) overall response rate and a 50% (6/12) complete response rate, with a well-managed safety profile in Relapsed/Refractory Hodgkin Lymphoma patients
Despite NTC014, due to its simplified therapeutic regimen, has been administered at a lower posology than the antibiotic comparator
Iskra has held leadership positions across Central & Eastern Europe, Eurasia, Middle East & Africa at AstraZeneca
For people with relapsed or refractory diffuse large B-cell lymphoma
The approved product has an estimated market size of US$ 106 million for the twelve months ending October 2024, according to IQVIA
Granules has undertaken a proactive, voluntary and comprehensive remediation plan to address the six form 483 observations raised by the USFDA
The celebrations began with the unveiling of the Biocon Anthem
She will be responsible in this role for Finance & Controlling, HR Services and IT Management at Romaco Holding
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xalatan
Subscribe To Our Newsletter & Stay Updated
